This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eggert, A. Articles by Evans, A. E. Search for Related Content PubMed PubMed Citation Articles by Eggert, A. Articles by Evans, A. E. Social Bookmarking                            What's this?

Expression of the Neurotrophin Receptor TrkB Is Associated With Unfavorable Outcome in Wilms’ Tumor

From the Division of Oncology and Biostatistics, The Children’s Hospital of Philadelphia, Philadelphia, PA.

Address reprint requests to Audrey E. Evans, MD, The Children’s Hospital of Philadelphia, Division of Oncology, ARC Room 902-D, 3516 Civic Center Blvd, Philadelphia, PA 19104; email: evansa{at}email.chop.edu

PURPOSE: Neurotrophins and their receptors regulate the proliferation, differentiation, and death of neuronal cells, and they have been implicated in the pathogenesis and prognosis of neuroblastomas and medulloblastomas. Tyrosine kinase (Trk) receptors also are expressed in extraneural tissues.

PATIENTS AND METHODS: To study the role of neurotrophin receptors and ligands in Wilms’ tumor (WT), we determined their expression by semiquantitative duplex reverse transcriptase polymerase chain reaction in 39 patients with primary WT. Comparison of mRNA expression levels with clinical variables was performed by use of Cox regression analysis.

RESULTS: Children with WT that expressed high levels of full-length TrkB mRNA (TrkBfull) had a significantly greater risk of death than children whose tumors had little or no TrkBfull expression (hazard ratio, 9.7; P = .02). The 5-year relapse-free survival was 100% versus 65% for patients with low versus high tumor expression of TrkBfull (P < .003). Conversely, children with tumors that expressed high mRNA levels of a functionally inactive truncated TrkB receptor (TrkBtrunc) had a greater chance of survival than children with low levels of TrkBtrunc (hazard ratio, 0.08; P = .005). The 5-year relapse-free survival was 95% versus 68% for patients with high versus low levels of TrkBtrunc (P = .01). The hazard ratios for TrkBfull and TrkBtrunc remained significant after they were adjusted for tumor stage (P = .01 and P = .017, respectively). All WTs with high levels of TrkB expression also expressed the brain-derived nerve growth factor ligand.

CONCLUSION: Expression of TrkBfull in WT is associated with worse outcome, perhaps because it provides an autocrine survival pathway. Conversely, TrkBtrunc expression is associated with excellent outcome, perhaps as a result of a dominant negative effect.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. J. Thiele, Z. Li, and A. E. McKee On Trk--The TrkB Signal Transduction Pathway Is an Increasingly Important Target in Cancer Biology Clin. Cancer Res., October 1, 2009; 15(19): 5962 - 5967. [Abstract] [Full Text] [PDF]

				G. M. Brodeur, J. E. Minturn, R. Ho, A. M. Simpson, R. Iyer, C. R. Varela, J. E. Light, V. Kolla, and A. E. Evans Trk Receptor Expression and Inhibition in Neuroblastomas Clin. Cancer Res., May 15, 2009; 15(10): 3244 - 3250. [Abstract] [Full Text] [PDF]

				Z. Li, G. Beutel, M. Rhein, J. Meyer, C. Koenecke, T. Neumann, M. Yang, J. Krauter, N. von Neuhoff, M. Heuser, et al. High-affinity neurotrophin receptors and ligands promote leukemogenesis Blood, February 26, 2009; 113(9): 2028 - 2037. [Abstract] [Full Text] [PDF]

				K.-i. Inoue, K. Ito, M. Osato, B. Lee, S.-C. Bae, and Y. Ito The Transcription Factor Runx3 Represses the Neurotrophin Receptor TrkB during Lineage Commitment of Dorsal Root Ganglion Neurons J. Biol. Chem., August 17, 2007; 282(33): 24175 - 24184. [Abstract] [Full Text] [PDF]

				T. R. Geiger and D. S. Peeper Critical Role for TrkB Kinase Function in Anoikis Suppression, Tumorigenesis, and Metastasis Cancer Res., July 1, 2007; 67(13): 6221 - 6229. [Abstract] [Full Text] [PDF]

				T. R. Geiger and D. S. Peeper The Neurotrophic Receptor TrkB in Anoikis Resistance and Metastasis: A Perspective Cancer Res., August 15, 2005; 65(16): 7033 - 7036. [Abstract] [Full Text] [PDF]

				W. Li, P. Kessler, H. Yeger, J. Alami, A. E. Reeve, R. Heathcott, J. Skeen, and B. R.G. Williams A Gene Expression Signature for Relapse of Primary Wilms Tumors Cancer Res., April 1, 2005; 65(7): 2592 - 2601. [Abstract] [Full Text] [PDF]

				K. M. Cronk, G. A. Wilkinson, R. Grimes, E. F. Wheeler, S. Jhaveri, B. T. Fundin, I. Silos-Santiago, L. Tessarollo, L. F. Reichardt, and F. L. Rice Diverse dependencies of developing Merkel innervation on the trkA and both full-length and truncated isoforms of trkC Development, August 1, 2002; 129(15): 3739 - 3750. [Abstract] [Full Text] [PDF]